Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Imunon Inc (IMNN)

Imunon Inc (IMNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,631
  • Shares Outstanding, K 3,923
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,620 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 2.13
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.99
  • Number of Estimates 2
  • High Estimate $-0.69
  • Low Estimate $-1.29
  • Prior Year $-3.65
  • Growth Rate Est. (year over year) +72.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +27.78%
on 03/25/26
3.59 -10.31%
on 03/04/26
-0.07 (-2.13%)
since 03/02/26
3-Month
2.52 +27.78%
on 03/25/26
4.20 -23.33%
on 01/05/26
-0.73 (-18.48%)
since 01/02/26
52-Week
2.52 +27.78%
on 03/25/26
41.22 -92.19%
on 06/02/25
-10.48 (-76.49%)
since 04/02/25

Most Recent Stories

More News
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical...

IMNN : 3.22 (+7.69%)
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated...

IMNN : 3.22 (+7.69%)
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026

LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the...

IMNN : 3.22 (+7.69%)
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the...

IMNN : 3.22 (+7.69%)
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered...

IMNN : 3.22 (+7.69%)
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Enrollment in the Pivotal Phase 3 OVATION  3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE,...

IMNN : 3.22 (+7.69%)
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced...

IMNN : 3.22 (+7.69%)
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with...

IMNN : 3.22 (+7.69%)
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders,...

IMNN : 3.22 (+7.69%)
IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10 th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON...

IMNN : 3.22 (+7.69%)

Business Summary

Imunon Inc. is a fully integrated, clinical stage biotechnology company. It focused on advancing a portfolio of treatments which harness the body's natural mechanisms. The company's lead clinical program includes GEN-1. Imunon Inc., formerly known as Celsion Corporation, is based in LAWRENCEVILLE, N.J....

See More

Key Turning Points

3rd Resistance Point 3.75
2nd Resistance Point 3.49
1st Resistance Point 3.36
Last Price 3.22
1st Support Level 2.97
2nd Support Level 2.71
3rd Support Level 2.58

See More

52-Week High 41.22
Fibonacci 61.8% 26.43
Fibonacci 50% 21.87
Fibonacci 38.2% 17.30
Last Price 3.22
52-Week Low 2.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.